PSYCHOTHERAPY FOR ADOLESCENTS, CHildren AND ADULTS
CYB003 is a next-generation psilocybin designed to provide a faster onset of action and to reduce the duration of effects, ultimately thinning the financial barrier to access of this medicine in a medical setting.
The trial’s interim data demonstrated “rapid, robust, and clinically significant reduction of depression symptoms” three weeks after a single 12mg dose of CYB003.
Read moreThis recently published study showed that psilocybin use is associated with persisting improvements in mental health and wellbeing.
Read moreThis pilot study demonstrated the safety, feasibility, and possible efficacy of psilocybin-assisted group therapy for cancer patients dealing with depressive symptoms.
Read moreKeep reading for an interview with the patient thought to be the first person to receive psilocybin under Oregon’s new system. He discusses his psilocybin experience.
Read morePsilocybin therapy for depression appears to have a curious effect on the brain’s response to music.
Read morePsilocybin is both serotonergic and anti-inflammatory and therefore may offer significant therapeutic benefits to patients with mental illness secondary to autoimmune inflammation.
Read moreIt has shown to be effective in treating post-traumatic stress disorder, depression and end-of-life anxiety.
Since then, regulations and restrictions for psilocybin treatment have taken shape across the state with many rural counties opting out of providing any psilocybin-related services at all.
Read moreThis occurred in patients with both curable and metastatic cancer.
Read moreIncluded is information on the therapeutic timeline, common effects, psilocybin-assisted therapy study designs, clinical trial findings, and participant reports.
